Reports that the CLL drug ofatumumab (Arzerra) is to be discontinued have been rejected by distributor Novartis. On 22 January the company from which the drug is licensed, Genmab, announced that the monoclonal antibody treatment was to be withdrawn in all markets outside the US due to low usage. The company said ofatumumab would be ...
Reports of Arzerra’s demise are greatly exaggerated
By Michael Woodhead
2 Feb 2018